Cancers have been a worldwide health problem with a high mortality rate, but ideal biomarkers are not available to effectively screen and diagnose patients. Currently, an increasing number of long noncoding RNAs have been reported to be abnormally expressed in human carcinomas and play a vital role in tumourigenesis. Plasmacytoma variant translocation 1 (PVT1) is upregulated in various carcinomas, and its overexpression is associated with poor survival in cancer patients. We conduct an updated meta-analysis to determine its potential in prognosis for tumours. In total, 14 studies Additionally, increased PVT1 expression was positively associated with lymphatic node metastasis (odd ratio [OR] = 2.87, 95% CI: 1.66-4.96, P = 0.0002), distant metastasis (OR = 2.47, 95% CI: 1.74-3.50, P < 0.00001), advanced tumour-node-metastasis stages (OR = 2.59, 95% CI: 1.38-4.88, P = 0.003). New findings highlight that PVT1 acts as competing RNA to microRNAs to protect mRNAs from miRNAs repression. Therefore, we also discuss PVT1-related microRNAs and their interaction in tumourigenesis. In conclusion, PVT1 may be a potential biomarker of poor prognosis for patients with different cancer types.
At present, cancer patients, especially those with high-risk features, such as lymph node metastasis (LNM), distant metastasis (DM), or late-stage tumours, exhibit a high mortality rate and a poor 5-year survival rate. Currently, no ideal biomarkers are available to screen or diagnose cancer effectively. Therefore, the identification of a new biological target that plays a guiding role in carcinogenesis is urgently needed to detect cancer and predict survival.
Long noncoding RNAs (lncRNAs) are referred to RNAs longer than 200 nucleotides and lack of protein-coding capacity given the absence of open-reading frames. 2 Recent reports suggest that lncRNAs play a vital role in carcinogenesis and the development of cancers. 3 With the application of high-throughput RNA sequencing techniques, abundant lncRNAs were identified. 4 Accumulating evidence demonstrates that lncRNAs play multiple and critical roles in the initiation and progression of various cancers and noncancerous diseases.
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The human PVT1 gene, which is homologous to the mouse plasmacytoma variant translocation gene 1, was originally defined as a cluster of chromosomal translocation or viral integration breakpoints and is a long intergenic noncoding RNA (lincRNA). 9 The human PVT1 lies in human band 4 of region 2 on the long arm of chromosome 8 (8q24) . This locus is a recognized cancer risk locus with the top target of copy number alterations and is also located near the well-known avian myelocytomatosis viral oncogene homolog (MYC) oncogene. 10 Moreover, the PVT1 locus gives rise to several alternatively spliced noncoding transcripts, 11 and PVT1 is the host to a cluster of microRNAs (miRNAs), including miR-1204, miR-1205, miR-1206, miR-1207-5p, miR-1207-3p, and miR-1208. 12 Recent evidence indicates that PVT1 is dysregulated in various human carcinomas, including gastric cancer (GC), 5, 8, [13] [14] [15] [16] lung cancer, 6,17-22 colorectal cancer (CRC), 23 oesophageal cancer, 24 pancreatic cancer (PC), [25] [26] [27] hepatocellular carcinoma (HCC), [28] [29] [30] breast cancer, 31 cervical cancer (CC), 32, 33 head and neck squamous cell carcinoma (HNSCC), 34 ovarian cancer (OC), 35 osteosarcoma, 1 , melanoma, 38 and noncancerous diseases. 7, 8 Furthermore, PVT1 overexpression is associated with clinicopathological characteristics in various cancers with high levels of PVT1 indicating poor overall survival (OS), disease-free survival (DFS), and/or progression-free survival (PFS). 5, 6 PVT1 contributes to tumour cell proliferation, migration, and invasion in various cancer cells via various mechanisms. Wu et al 25 revealed
that PVT1 could transcriptionally downregulate p21 and increase zinc finger E-box-binding protein 1 (ZEB1) and Snail expression, thus promoting cell migration and proliferation in PC. PVT1 is negatively correlated with p15 and p21 expression. PVT1 overexpression promotes cell proliferation and increases the number of S-phase cells in nonsmall cell lung cancer (NSCLC). 17 In addition, overexpression of PVT1 was found both in tissues and cells of cisplatin-resistant GC patients and potentially improves the expression of MDR-related genes, such as multidrug resistance 1 (MDR1), mammalian target of rapamycin, MDR-associated protein 1 (MRP1) and hypoxia-inducible factor-1 alpha (HIF-1α), in cisplatin-resistant GC cells. 8 Multidrug resistance (MDR) is one of the major reasons for therapeutic failure in human cancers, which leads to recurrence, metastasis, and poor survival for cancer patients. Hence, an increasing focus is given to the clinical application of PVT1 as a potential biomarker and therapeutic target in diverse cancers. 34 GC, 15 and acute myeloid leukaemia. 44 However, its function in human cancers remains largely unknown and even contradictory.
In this review, we will discuss the current state of PVT1, including circPVT1 in cancers, with particular emphasis on their potential clinical significance in cancer prognosis assessment and possible mechanism in carcinogenesis and tumour progression.
| MATERIAL S AND ME THODS

| Publication search strategy
We searched various databases, including PubMed, Web of Science, Cochrane Library, China National Knowledge Infrastructure (CNKI),
and Wanfang for eligible studies published up to 1 February 2018.
The following keywords were used for the searches: "plasmacytoma variant translocation 1 or PVT1" AND "cancer or tumour or carcinomas or neoplasm." Furthermore, the references in these eligible articles were also manually reviewed to identify potentially relevant studies.
Checklists Criteria
Samples
Retrospective or prospective cohort design with a well-defined study population Medical treatment applied to the patients was explained; and authors have explained if all patients have received the same treatment or no
Clinical data of the cohort
The basic clinical data such as age and gender were provided 3. qRT-PCR Clearly described primers, quantitation methods or referred to original paper
Specimen characteristics
Primary resected tumour specimens and adjacent normal tissues
Prognostication
The analysed survival endpoints were defined (eg, overall survival, disease-free survival) 6 . Statistics Cut-off point, used to divide the cases into risk groups, was well described Estimated effect (HR, CI) describing the relationship between the evaluated PVT1 and the outcome (overall survival, disease-free survival, or progression-free survival) was provided Adequate statistical analysis (eg, Cox regression modelling) was performed to adjust the estimation of the effect of PVT1 for known prognostic factors REMARK: reporting recommendations for tumour marker prognostic studies; PVT1: plasmacytoma variant translocation 1; qRT-PCR: quantitative real-time reverse transcription polymerase chain reaction; HR: hazard ratio; CI: confidence interval.
TA B L E 1 Evaluation criteria used to assess the quality of studies included in the meta-analysis of PVT1 (adapted from REMARK guidelines)
| Inclusion and exclusion criteria
Two investigators independently assessed and extracted data from all eligible studies. The Reporting Recommendations for Tumour Marker Prognostic Studies (REMARK) guidelines 45, 46 were used to evaluate the quality of studies, and the selected guidelines taken from the REMARK criteria are summarized in Table 1 
| Data extraction and quality control
According to the inclusion and exclusion criteria, two investigators (XMZ, FY) independently extracted data from the eligible studies, and disagreements were discussed and resolved through consensus with two additional reviewers (LCD, ZZY 
| Statistical analysis
All extracted data analyses were performed with Review 45 Subgroup and sensitivity analyses were performed to analyse the sources of heterogeneity. 47 The agreement among authors (XMZ, FY) who performed the screening was evaluated using Cohen's kappa coefficient. (mean, 147). The studies were performed in three countries (12 from China, 1 from Japan, and 1 from India).
The basic characteristics of the included studies, of which two studies included two sets of patients and two studies analysed the association between circPVT1 and prognosis of patients, are summarized in Table 2 . These included studies with clinical characteristics, such as gender, TNM stage, LNM, DM, invasion depth, vascular invasion, and lymphatic invasion in high-expression and low-expression PVT1, are presented in Table 3 . Among these 14 studies, eight different cancer types were evaluated in this metaanalysis: seven studies on digestive system carcinomas, including one oesophageal squamous cell carcinomas, 24 four GCs, [13] [14] [15] 49 one CRCs, 50 and one PCs
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; two on urogenital system carcinoma, including one OC 35 and one clear cell renal cell carcinoma (ccRCC) 51 ; four on respiratory system carcinomas, including three NSCLCs 17, 19, 20 and one small cell lung cancer (SCLC) 18 ; and other systems, including one HNSCC. 34 Cut-off value for high or low PVT1 expression was defined by either mean, median, or percentile value. No patient received chemotherapy or radiotherapy before surgery, and all the diagnoses of clinical characteristics were based on histopathology.
| Association between PVT1 and OS in cancers
Pooled HRs for OS were all extracted directly from 13 studies.
Twelve studies with a total of 1876 patients reported an association between PVT1 expression and OS; the pooled HR was 1.98 (95% CI: 1.62-2.42, P < 0.00001), indicating that PVT1 overexpression predicted poor OS for patients with these carcinomas. The random-effect model was adopted because of significant heterogeneity (I 2 = 53%, P = 0.01) ( Figure 3A ). As shown in Table 4 , subgroup analyses were conducted based on various cancer types, cut-off values, and sample sizes. The stratified analysis by various cancer types indicated a significant association between increased PVT1 expression and poor OS in patients with digestive system carcinomas (HR = 2.13, 95% CI: 1.57-2.89, P < 0.00001), respiratory system carcinomas (HR = 2.34, 95% CI: 1.64-3.34, P < 0.00001), and urogenital system carcinomas (HR = 1.53, 95% CI: 1.19-1.96, P = 0.0008) ( Figure 4A ). Next, we performed subgroup analyses stratified by cut-off value, and high PVT1 expression was significantly associated with poor OS in the studies using median (HR = 2.04, 95% CI:
1.62-2.57, P < 0.00001) and others (HR = 1.93, 95% CI: 0.89-4.15, P = 0.09) ( Figure 4B ). Then, we divided the studies into two categories according to the sample size using 100 patients as a threshold.
In this analysis, upregulated PVT1 expression was a strong prognostic marker for poor OS both in larger sample sizes (HR = 1.52, 95%
CI: 1.33-1.73, P < 0.00001) and smaller sample sizes (HR = 2.62, 95% CI: 1.98-3.48, P < 0.00001) ( Figure 4C ). Two studies reported the association between circPVT1 expression and OS, but no significance was found (HR = 1.21, 95% CI: 0.52-2.83, P = 0.66) as shown in Figure 3C .
| Association between PVT1 and DFS in cancers
Seven studies comprising 1406 patients reported the prognostic value of PVT1 for DFS or PFS. As shown in Figure 3B , PVT1 overexpression was a negative factor for DFS (HR = 1.63, 95% CI:
1.45-1.84, P < 0.00001) with no significant heterogeneity among studies (I 2 = 0%, P = 0.85). Then, we conducted subgroup analyses based on cancer type, sample size, and cut-off value. These data are presented in Table 5 and supplementary Figures S1-S3.
The stratified analysis by cancer type indicated a significant association between increased PVT1 expression and poor DFS in patients with digestive system carcinomas (HR = 1.70, 95% CI:
1.36-2.13, P < 0.00001). Then, high PVT1 expression was significantly related to poor DFS in the studies using median (HR = 1.64, 95% CI: 1.45-1.86, P < 0.00001) as the cut-off value. In addition, upregulated PVT1 expression was a strong prognostic marker for poor DFS in studies with large sample sizes (HR = 1.61, 95% CI:
1.40-1.84, P < 0.00001) or with small sample sizes (HR = 1.75, 95%
CI: 1.37-2.24, P < 0.00001) using 100 patients as the threshold to group. Given that all these stratified analyses exhibit no heterogeneity, a fixed-effect model was applied.
| Association between PVT1 and clinicopathological characteristics
The pooled ORs and 95% CIs of the clinicopathological characteristics for all the enrolled studies are presented in Table 6 and The study about ovarian cancer was not involved because there were only female patients in the study. 
| D ISCUSS I ON
In recent years, an increasing number of studies demonstrated that lncRNAs were abnormally expressed in various cancers and some could even serve as potential markers for diagnosis, prognosis, and treatment in malignant tumours. Therefore, numerous reviews or meta-analysis articles, including our study, have been used to reveal the correlation between lncRNAs and cancer progression and prognosis. 47, 52 The PVT1 gene was first discovered in 1983 in mouse as frequently involved in plasmacytomas. 9, 53 Shortly thereafter, the PVT1 locus also emerged in human Burkitt's lymphomas as a site of variant translocations. 54 Since then, PVT1 has been an area of focused research especially in recent decades, which is reflected by the increasing number of publications related to PVT1 as shown in Figure 1 . suggesting that hsa_circ_002059 may be a potential stable biomarker for the diagnosis of GC. 41 In contrast, only a few studies have reported that the expression and function of circPVT1 in human diseases to date. CircPVT1, which was first identified as has-circRNA 6 by Memczak et al, 40 originates from the PVT1 transcript. CircPVT1 is a 410-nt long circRNA and results from the circularization of PVT1 exon2. 15, 34, 44, 67 Panda et al 67 revealed
that knockdown of circPVT1 in proliferating fibroblasts triggered senescence and reduced cell proliferation with an increase in senescence-associated β-galactosidase activity and increased cyclin-dependent kinase inhibitor 1A (CDKN1A)/P21 and TP53 levels. Moreover, circPVT1 directly binds to let-7 and antagonizes endogenous let-7 triggered cell proliferation. 67 Verduci L et al was upregulated in GC tissues partly due to DNA amplification.
In addition, circPVT1 promotes cell proliferation by sponging miR-125 family members to inhibit its activity and facilitating E2F2 expression. 15 However, partly contrary to Lorena's findings, low circPVT1 expression was related to poor OS and DFS for GC patients. 15 The circRNAs are more stable than associated linear mRNAs in vivo given their resistance to RNase activity; 40, 68 hundreds of circRNAs are more abundant in blood than corresponding linear mRNAs. 69 Therefore, further studies are needed to explore the expression of circPVT1 in tumours and its function in carcinogenesis and development. In addition, circPVT1 may be a more potent biomarker of prognosis or detection in for tumour patients. only English-or Chinese-language publications were included in this meta-analysis, so studies in other languages demonstrating the association of PVT1 expression and cancer patients' survival were ignored.
In conclusion, our meta-analysis suggested that PVT1 could sever as a molecular biomarker to predict the clinicopathological characteristics and prognoses for tumour patients. Specifically, high PVT1 expression indicates an increased risk of metastasis and poor survival. The function and mechanism of circPVT1 in tumour progression requires further study. Importantly, PVT1 acts as ceRNA or directly binds to miRNAs in the tumourigenesis and development. 
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